Phase 3 PREVAIL Study Delivers Promising Results in Prostate Cancer Patients

The results of the Phase 3 Prevail Study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.

The results of the Phase 3 PREVAIL study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.

Enzalutamide did translate to significant overall survival to an unprecedented extent,” said Prof. Bertrand Tombal (BE) during the Late Breaking News segment of the concluding plenary session of the 29th Annual EAU Congress which ends today in Stockholm, Sweden.

Bertrand said the results of the main study and the European regional results of the phase 3 randomised PREVAIL study also has to be considered in a very rapidly changing treatment landscape when new prostate cancer drugs are emerging.

“Enzalutamide also has impact on other points such as time- to-PSA progression and has demonstrated a tolerability profile comparable to placebo,” he noted. “One of the clinical benefits is the ability to use this agent in second-line hormonal manipulation.”

Read the complete news report here: http://bit.ly/QayKhy

Source: EAU News